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The posttranslational modification of proteins by 
fatty acids has been shown to involve long chain-satu- 
rated  fatty acids, predominantly  palmitate. In the  pres- 
ent  study, we demonstrated by metabolic labeling of 
human platelets  with [3H]arachidonate and [3H]eico- 
sapentaenoate that these  polyunsaturated fatty acids 
can also become covalently linked to proteins. The 
extent of binding of arachidonate  to  proteins was some- 
what less than  that of palmitate.  Arachidonate  binding 
to  platelet  proteins  was not significantly influenced by 
the inhibition of cyclooxygenase and lipoxygenase. 
This  finding  and  the high performance  liquid  chroma- 
tography analysis of radiolabeled products removed 
from  proteins by selective  cleavage  techniques  estab- 
lished that  arachidonate,  and not its metabolic prod- 
ucts, was  the  protein-linked  radiolabeled moiety in [3H] 
arachidonate-labeled  platelets. A ‘7.5-fold higher con- 
centration of unlabeled palmitate competed to  a small 
extent  with [3H]arachidonate for  protein labeling. Both 
arachidonate and eicosapentaenoate were bound to 
proteins almost exclusively through  ester  linkages. It 
was further demonstrated that 61 and 66% of total 
protein-linked arachidonate and eicosapentaenoate, 
respectively,  were bound via  thioester bonds. In con- 
trast, 91% of the  binding of palmitate  to  proteins oc- 
curred via thioester linkages. As demonstrated by 
SDS-polyacrylamide gel electrophoresis  and fluorog- 
raphy,  the  patterns of palmitoylated and  arachidon- 
oylated proteins  were  similar  but not identical,  with 
selected proteins only palmitoylated or only arachidon- 
oylated. [‘HIEicosapentaenate labeled the  same  set of 
proteins as [3H]arachidonate. The  fluorographic  pat- 
tern of 3H-arachidonoylated proteins  was not changed 
by cyclooxygenase and lipoxygenase inhibitors. The 
binding of a polyunsaturated fatty acid to a  protein  in 
place of a saturated  fatty acid could significantly  influ- 
ence the hydrophobic interactions of the  protein  and, 
thereby,  have  important  functional implications. 
Covalent attachment of a  fatty acid to  an amino acid residue 
results in the addition of a hydrophobic moiety to  the protein. 
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This may facilitate the interaction of the protein with hydro- 
phobic membrane domains, promote hydrophobic protein- 
protein  interactions, or target  proteins to  specific membrane 
receptors (for reviews,  see  Refs. 1-4). Fatty acids can be linked 
to  an amino acid residue directly or indirectly as  a component 
of a phosphatidylinositol moiety attached to a COOH-termi- 
nal amino acid through an intervening glycan structure (5,6). 
Direct linkage of fatty acids to proteins  can occur both co- 
translationally and posttranslationally. The former type of 
modification involves an NHz-terminal amino acid residue to 
which the  fatty acid is bound through an amide bond. The 
enzyme which is responsible for this type of modification, N- 
myristoyl transferase,  has been purified, and  the gene for the 
protein  has been cloned. This  protein was found to exhibit 
strict substrate specificity toward myristoyl-CoA as a fatty 
acid donor and  NHz-terminal glycine as  fatty acid acceptor 
(7-12). The biochemical mechanism of posttranslational  fatty 
acid acylation of proteins  has  not been studied to  the same 
extent as cotranslational N-myristoylation. The enzyme(s) 
responsible for addition of thioester-linked  fatty acids have 
not been isolated, and  the amino acid sequence requirement 
around the cysteine residue which is involved in  the linkage 
is not known. From a number of studies in which cells were 
incubated with radiolabeled palmitate,  and  proteins were co- 
valently bound to  this  fatty acid, it was concluded that pal- 
mitate is the  fatty acid involved in this type of modification. 
However, data from a few reports have indicated that  fatty 
acid acylation through  thioester linkages has  a more relaxed 
fatty acid specificity than cotranslational  fatty acid acylation. 
Using microsomal membrane fractions to study  protein acy- 
lation with a viral polypeptide as  a  fatty acid acceptor, it has 
been shown that myristate,  stearate,  and oleate could replace 
palmitate  as the thioester-linked  fatty acid (13).  In  cultures 
of epidermoid carcinoma cells, mouse fibrosarcoma cells, and 
rat pheochromocytoma cells, myristate  and  stearate were also 
bound to proteins by ester, probably thioester linkages, al- 
though the  extent of binding was significantly less than  that 
of palmitate (14, 15). More recently, we have shown that in 
human  platelets,  in which de novo protein  synthesis is negli- 
gible and, therefore, no cotranslational fatty acid acylation 
takes place, palmitoylation is an active process (16, 17), and 
that myristate also becomes bound to platelet proteins via 
thioester linkages (18). Taken together, these results establish 
that  saturated long chain  fatty acids other  than palmitate can 
be utilized to posttranslationally acylate proteins. The in- 
volvement of polyunsaturated  fatty acids in the posttransla- 
tional  fatty acid acylation of proteins  has  not been studied, 
although the covalent binding of arachidonate metabolites, 
eicosanoids, to proteins  has also been detected in microsomal 
cell fractions (19-21) and in intact platelets (22). In the 
present study, it was demonstrated in human platelets by 
metabolic labeling with [3H]arachidonate  and [3H]eicosapen- 
taenate  that these  polyunsaturated  fatty acids could  become 
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covalently bound to proteins.  Furthermore, the  extent of their 
binding was comparable to  that of palmitate.  This binding 
was not prevented by lipoxygenase and cyclooxygenase inhib- 
itors  and occurred almost exclusively via ester,  predominantly 
thioester, linkages. As demonstrated by SDS-PAGE' and 
fluorography, most of the proteins that  are palmitoylated can 
also be acylated with arachidonate and eicosapentaenoate, 
although there were proteins which were acylated only by 
palmitate. 
EXPERIMENTAL  PROCEDURES 
Materials-[5,6,8,9,11,12,14,15-3H]Arachidonate (76 Ci/mmol), 
[5,6,8,9,11,12,14,15,17,18-3H]eicosapentaenoate (116.8 Ci/mmol), 
[9,10-3H]palmitate (38.0 Ci/mmol), and scintillation solution F 989 
were purchased from  Du Pont-New England Nuclear. Arachidonate, 
palmitate, docosahexaenoate (22:6), arachidonate methyl ester, and 
docosatetraenoate methyl ester (22:4) were products of Nu-Check 
Prep (Elysian, MN). Hydroxylamine, apyrase (grade VII), fatty acid 
free bovine serum albumin and eicosapentaenoate methyl ester were 
obtained from Sigma. Eicosapentaenoate was a product of Cayman 
Chemical Co. (Ann Arbor, MI). M, marker  proteins were purchased 
from Bio-Rad. Prostaglandin El (PGE,) was purchased from Seragen 
(Cambridge, MA). Baicalein, a selective inhibitor of platelet lipoxy- 
genase (23), was the product of Biomol (Plymouth Meeting, PA). The 
water-soluble indomethacin megluminate was obtained from Chiesi 
Farmaceutici S. p.  A. (Parma, Italy). ',C-Methylated M, marker 
proteins and autoradiographic image enhancer (Amplify) were ob- 
tained from Amersham Corp. HPLC grade solvents were used for 
HPLC, delipidation of proteins,  alkaline methanolysis, and extraction 
of fatty acids. Methanolic HCI (3 M) was the product of Supelco 
(Bellefonte, PA). Methylation of docosahexaenoate acid was per- 
formed according to  the method of Lepage and Roy (24). 
Preparation of PHIFatty Acid-labeled Platelet Suspensions-The 
procedure described earlier for labeling with [3H]palmitate was fol- 
lowed with minor modifications (16). Platelet-rich plasma was ob- 
tained from human blood anticoagulated with acid-citrate-dextrose 
containing 0.18 p M  PGE, by centrifugation (120 X g, 15 min). Plate- 
lets pelleted from platelet-rich plasma at 1300 X g (15 min) were 
resuspended in solution A (140 mM NaQ2.5 mM KC],  0.1 mM MgCL, 
10 mM NaHC03, 0.5 mM NaH2 PO,, 1 mg/ml glucose, 10 mM HEPES, 
pH 7.4) containing 3.6 mg/ml fatty acid-free bovine serum albumin, 
1 unit/ml apyrase, and 0.3 p M  PGE,. [3H]Arachidonate, [3H]eicosa- 
pentaenoate,  or  [3H]palmitate  in  ethanol was dried completely under 
nitrogen, then solubilized by vigorous mixing for 60 s in the above 
solution, and added to  an equal volume of platelet suspension. After 
the incubation for 1 h, total radioactivity was determined. Platelets 
were then pelleted by centrifugation (1100 X g, 15 min) and resus- 
pended in the same volume of solution A  containing 1 unit/ml apyrase 
and 0.3 p~ PGE,. Platelets were again centrifuged (1100 X g, 15 min) 
and resuspended in solution A containing 1 unit/ml apyrase and 
incubated for an additional 30 min. Finally, aliquots were  removed 
for the determination of platelet count and radioactivity incorporated 
in the platelets. The  entire procedure was carried out a t  37 "C. During 
centrifugation, the temperature in the centrifuge was maintained 
between 32 and 37  "C. The radioactivity in the final suspension was 
300 pCi/ml which corresponded to mass concentrations of 4 p M  for 
arachidonate, 2.6 pM for eicosapentaenoate, and 7.9 pM for palmitate, 
which are in the physiological range for nonesterified fatty acids 
bound to albumin (25). The platelet  count was  300-330 X 10 6/ml. In 
certain experiments with [3H]arachidonate and 13H]palmitate, the 
incubation mixture also contained 30 /IM unlabeled palmitate. In  the 
experiments with cyclooxygenase and lipoxygenase inhibitors, the 
platelet suspension and  the washing solutions contained  10 p M  bai- 
calein and 30 p~ indomethacin. In separate experiments, it was shown 
that under these conditions both the cyclooxygenase and lipoxygenase 
pathways of eicosanoid production were completely inhibited. 
Extraction of Noncovalently Bound Lipids-Washed radiolabeled 
platelets (1 ml) were precipitated and extracted with 3.5 volumes of 
cold acetone (vortexing for 60 s) and  then kept on ice for 30 min, at 
which time the precipitate was collected by centrifugation (4500 Xg, 
4 "C, 10 min). Acetone-precipitated proteins from 1 ml of platelet 
The abbreviations used are: PAGE, polyacrylamide gel electro- 
phoresis; HPLC, high performance liquid chromatography; PGE1, 
prostaglandin E,; dpm, disintegrations/minute. 
suspension were first extracted with 6 ml of chloroform/methanol 
(2:l).  The mixture was vortexed for 60 s and  then incubated at room 
temperature for 30 min. The protein precipitate, pelleted by centrif- 
ugation (4500 X g, room temperature, 15 min), was extracted twice 
more with 6 ml of the same chloroform/methanol (2:l) solvent, then 
twice with 6 ml of chloroform/methanol/water (1:1:0.3), and finally 
with methanol. After each extraction  step, the samples were left at 
room temperature for 10 min before centrifugation. The final protein 
residue contained no radioactivity removable by lipid extracting sol- 
vents, and  it was dried completely under nitrogen. Selected protein 
samples were dissolved in SDS-PAGE sample buffer (without p- 
mercaptoethanol) by boiling for 5 min and  then shaking overnight. 
Their protein content  and radioactivity were determined. Other  sam- 
ples were used for the release of fatty acids and identification and 
quantitation of the  fatty acids bound to proteins. 
Release of Protein-bound Fatty Acids by Alkaline and Acid Metha- 
nolysis and Identification of Released Fatty Acids by HPLC-The 
dried delipidated protein  preparations were first subjected to alkaline 
methanolysis to disrupt 0-ester and S-ester linkages and subse- 
quently subjected to acid methanolysis to disrupt amide linkages (16). 
Fatty acids released by alkaline  or acid methanolysis were extracted 
with hexane, then dried completely under nitrogen and redissolved 
in methanol. Aliquots were removed for determination of extracted 
radioactivity before HPLC analysis. The nonextractable radioactivity 
was also measured. To the remainder of the samples, 2.4  pg  of 
unlabeled fatty acid (arachidonate  or  eicosapentaenoate), and unla- 
beled fatty acid methyl esters (methyl arachidonate and methyl 22:4 
n-6 or methyl eicosapentaenoate and methyl 2 2 5  n-3) were added as 
standards.  Separation of fatty acids and fatty acid methyl esters was 
achieved by reverse-phase HPLC using a Microsorb C18 column (4.6 
mm X 30 cm, Rainin, Woburn, MA). The fatty acids were eluted with 
a 40-90% (v/v) acetonitrile, 17 mM phosphoric acid gradient for 20 
min and  then with 90% acetonitrile, 17 mM phosphoric acid for 35 
min at a flow rate of 1 ml/min. Fractions of 1 ml  were collected. The 
absorbance profile of eluted compounds was monitored at 205 nm, 
and retention times of radioactive alkaline methanolysis products 
were determined by coelution with unlabeled fatty acid and fatty acid 
methyl ester  standards. 
Release of Protein-bound Fatty Acids by Neutral Hydroxylamine 
Treatment-Delipidated platelet proteins from 0.1 ml of platelet 
suspension were resuspended in 0.5 ml of H20 with a 10-s burst of 
sonication. Equal volumes of 2 M hydroxylamine, pH 6.95,  were added 
and  the mixture was incubated for 12 h at room temperature with 
constant shaking. It was then extracted with 3 X 1 ml chloroform/ 
methanol (2:l). The organic phases were combined and dried com- 
pletely under nitrogen. The dried material was resuspended in 0.2 ml 
of acetonitrile and 0.1 ml of water. Then 4.5 ml of F989 was added, 
and  the radioactivity was determined. Alternatively, delipidated pro- 
teins dissolved in 50 p1 of SDS sample buffer were also treated with 
1 M hydroxylamine (pH 6.95) and extracted as described above. The 
amount of radioactivity released by neutral hydroxylamine was essen- 
tially identical using both methods. Treatment with 1 M Tris-HCI, 
pH 6.95, did not result in any release of radioactive material from the 
proteins. 
SDS-PAGE, Hydroxylamine Treatment, and Fluorography of Poly- 
acrylamide Gels-SDS-PAGE of reduced (with 50  mg/ml B-mercap- 
toethanol)  or nonreduced platelet proteins  in  a 5-20% gradient gel, 
as well as fixing, staining, and destaining of  gels, and 1 M hydroxyl- 
amine treatment of fixed gels have all been described earlier (16). 
Destained gels  were soaked in Amplify solution supplemented with 
0.5%  glycerol for 1 h, briefly rinsed with distilled HzO, and dried at 
60 "C. The dried gels were exposed to Kodak X-OMAT AR film 
(Rochester, NY) at -70 "C for 4 weeks. 
Other Methods-Protein concentration was measured with the 
BCA protein assay kit (Pierce Chemical Co.). Radioactivity was 
counted in a Beckman (Fullerton, CA) LS 6800 scintillation counter. 
RESULTS 
Uptake  and  Covalent  Binding to Proteins of PHIFatty 
Acids-A substantial  amount of added [3H]arachidonate 
(26.5% of the  total added radioactivity) was incorporated into 
platelets during the 1-h incubation period (Table I). The 
amount of dpm incorporated into cells incubated with [3H] 
arachidonate was approximately 2.5- and 3-fold higher than 
in [3H]eicosapentaenoate and [3H]palmitate-labeled platelets, 
respectively. The different amounts of incorporated radioac- 
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TABLE I
The incorporation  of radiolabeled fatty  acids into platelets 
Platelets were incubated with 300 pCi/ml of the [3H]fatty acid for 
1 h at 37 "C, and the radioactivity incorporated by the cells was 
determined. The concentration of nonlabeled palmitate, when pres- 
ent, was 30 p ~ .  Inhibitors: platelet lipoxygenase and cyclooxygenase 
were inhibited by baicalein and indomethacin. Values represent 
means f S.E. 
Components  in  the 
Incorporated radioactivity 
No. of 
incubation  m xture  exp riments  dpm/ng '% of added 
protein radioactivity 
[3H]Palmitate 10 93.9 f 3.5 9.5 f 0.3 
[3H]Arachidonate 7  259.0 f 9.5 26.5 f 1.0 
r3H1Arachidonate and 6 222.3 2 23.1 23.5 ? 2.4 
inhibitors 
[3H]Arachidonate and 3 221.9 2 7.5 23.9 f 0.8 
palmitate 
[3H]Eicosapentaenoate 2 118.0 f 1.2 11.8 f 0.1 
TABLE I1 
Covalent  binding of incorporated radiolabeled fatty  acids  to  platelet 
proteins 
Platelets were incubated with 300 pCi/ml of the [3H]fatty acid for 
1 h at 37 "C. Platelet  proteins were precipitated, noncovalently bound 
lipids were extracted, and protein-bound radioactivity was measured. 
The concentration of non-labeled palmitate, when present, was 30 
PM. Inhibitors: platelet lipoxygenase and cyclooxygenase  were inhib- 
ited bv baicalein and indomethacin. Values reuresent  means f S.E. 
~~ ~ 
Radioactivity covalently 
linked to  proteins 
Comoonents  i th  No. of 
incubation  mixture  experiments $::: incorporated '% of 
radioactivity 
[3H]Palmitate 8 1.91 f 0.06 2.03 f 0.06 
[3H]Arachidonate 5  1.72 2 0.11 0.66 f 0.04 
[3H]Arachidonate and 4 1.16 f 0.13 0.52 f 0.06 
[3H]Arachidonate and 3  1.13 f 0.10 0.51 f 0.04 
[3H]Eicosapentaenoate 2 0.68 f 0.01 0.58 f 0.01 
inhibitors 
palmitate 
tivity probably reflect differences in  the rates of fatty acid 
uptake. Incubation with cyclooxygenase and lipoxygenase in- 
hibitors slightly decreased the uptake of [3H]arachidonate. A 
7.5-fold excess of unlabeled palmitate resulted only in a slight 
decrease of incorporation of radiolabeled arachidonate, which 
is consistent with the concept that  in platelets two distinct 
mechanisms are involved in the uptake of saturated and 
polyunsaturated  fatty acids (26). 
A relatively small but reproducible portion of radioactivity 
(1.72 k 0.11 dpm/ng protein) became covalently linked to 
platelet proteins in [3H]arachidonate-labeled cells, which is 
somewhat less than  the value (1.91 f 0.06 dpm/ng  protein) 
obtained with [3H]palmitate  (Table 11). Since the amount of 
incorporated radioactivity in [3H]palmitate-labeled platelets 
is considerably lower than in [3H]arachidonate-labeled cells, 
the amount of protein-bound radioactivity obtained with [3H] 
palmitate  represents  a %fold higher percentage of total radio- 
activity incorporated in the cells than  that measured in [3H] 
arachidonate-labeled cells (2.03 k 0.06% versus 0.66 f 0.04%). 
Since the percentage of total  incorporated [3H]eicosapentae- 
noate that was linked to proteins was approximately the same 
(0.58 f 0.01%) as  the value obtained with [3H]arachidonate, 
the relatively low protein-bound dpm in [3H]eicosapentae- 
noate-labeled platelets (0.68 f 0.01 dpm/ng  protein)  is  appar- 
ently due to  the relatively low uptake of this  fatty acid rather 
than  to  the impaired binding of eicosapentaenoate to proteins. 
The incubation of platelets with baicalein and indomethacin 
resulting in the combined inhibition of platelet cyclooxygen- 
ase and lipoxygenase activities decreased the protein-linked 
radioactivity in [3H]arachidonate-labeled platelets by 33%. If 
the slight inhibition of uptake of [3H]arachidonate in these 
platelets was also taken  into  account,  the decrease was only 
21%. The presence of excess (30 PM) unlabeled palmitate 
resulted in  a 23% decrease in the binding of [3H]arachidonate 
to platelet  proteins. The same amount of unlabeled palmitate 
competed more efficiently with the posttranslational protein 
binding of [3H]myristate (18) and of [3H]palmitate than with 
the posttranslational  protein binding of [3H]arachidonate in 
Table I1 (51% inhibition for [3H]myristate, 61% inhibition 
for  [3H]palmitate,  and 23% inhibition for [3H]arachidonate). 
This was true despite the fact that  the experiments involving 
radiolabeled palmitate and radiolabeled myristate included 
these  fatty acids in higher mass concentrations (7.5 and 7.9 
PM, respectively) than experiments involving radiolabeled 
arachidonate (4 pM).  
Type of Linkages  and  Identity of Fatty  Acids  Involved  in 
Covalent  Bindings  to  Proteins-As reported earlier (16),  ra- 
holabeled  palmitate was bound to proteins almost exclusively 
via ester linkages. Similarly, more than 90% of the radioac- 
tivity bound to proteins in [3H]arachidonate  and [3H]eicosa- 
pentaenoate-labeled cells could be released from proteins by 
alkaline methanolysis, which disrupts all ester bonds (0-ester 
and  S-ester)  (Table 111). After alkaline methanolysis, for all 
three labeled fatty acids the release of radioactivity by acid 
methanolysis (i.e. fatty acids bound via amide linkages) as 
well as  the nonreleasable radioactivity that remained with the 
protein  after such treatment were  negligible. It was  shown by 
HPLC analysis that  in [3H]arachidonate  and [3H]eicosapen- 
taenoate-labeled cells, 95 and 92% of the radioactivity bound 
to protein through ester linkage was [3H]arachidonate and 
[3H]eicosapentaenoate, respectively (Fig. 1). This clearly in- 
dicates that predominantly arachidonate and eicosapentae- 
noate were bound to proteins  and  not  their metabolic prod- 
ucts. Neither the inhibition of cyclooxygenase and lipoxygen- 
ase nor the addition of cold palmitate influenced this 
situation, since the contribution of [3H]arachidonate to  the 
total of esterified protein-linked radioactivity was still greater 
than 90% under these conditions (data not shown). Using 
neutral hydroxylamine treatment which selectively cleaves 
thioester  but  not  0-ester bonds (27-29), nearly 100% of [3H] 
palmitate bound to protein via ester linkage was identified as 
thioester linked fatty acid (Table 111). The major portion of 
radiolabeled arachidonate and eicosapentaenoate was also 
bound to protein  through  thioester linkages. However, a minor 
but significant portion was  involved in other  type(s) of ester, 
probably 0-ester, linkages. The relative proportion of thioes- 
ter-linked [3H]arachidonate within the total protein-bound 
pool  was slightly decreased (61 versus 53%) when [3H]arach- 
idonate labeling of platelets was performed in the presence of 
30 pM unlabeled palmitate. 
Detection of PHJFatty Acid-labeled Proteins  by  SDS-PAGE 
and Fluorography-Studies were performed to determine if 
the two tritiated polyunsaturated fatty acids used in the 
experiments became bound to  the same set of proteins  as were 
labeled with [3H]palmitate. The fluorographic patterns of 
radiolabeled proteins from platelets separately incubated with 
[3H]arachidonate  and with [3H]palmitate were similar but not 
identical (Fig. 2, lanes P and A) .  Even using only one-dimen- 
sional electrophoresis, on the reduced gel, at least four pal- 
mitoylated bands  (129,47,  and 37, and 17 kDa) were identified 
(see arrowheads on lane P, reduced gel)  which had no corre- 
sponding band in lane A with arachidonoylated proteins. On 
the nonreduced gel, two such bands were also detected (see 
arrowheads, nonreduced gel, lane P). The absence of a band 
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TABLE I11 
Release of radiolabeled fatty acids covalently linked to platelet proteins by selective cleavage techniques 
Parallel samples of lipid extracted  proteins from platelets labeled with [3H]fatty acids were subjected to neutral hydroxylamine treatment 
to release thioester linked fatty acids or to alkaline methanolysis to release all ester linked fatty acids. The radioactivity liberated was 
determined by scintillation counting. Protein samples treated with alkaline methanolysis were subsequently subjected to acid methanolysis 
to release amide linked fatty acids. The radioactivity released, as well as the radioactivity remaining with the protein precipitate (nonreleasable 
pool), were determined. The percentage of radioactivity liberated by alkaline and acid methanolysis plus the nonreleasable pool sum to 100% 
in each case. Results are means of at least two separate experiments, the differences of which  were less than 4% (hydroxylamine treatment 
and alkaline methanolysis) or 2% (acid methanolysis and nonreleasable dpm). 
7% of total  protein-linked radioactivity 
Released by Fatty  acids  in  the 
incubation  mixture 




Neutral Methanolysis Nonreleasable 
hydroxylamine Alkaline Acid 
[3H]Palmitate ' 91 94 3 3 1980 
[3H]Arachidonate 61 93  3 4 1605 
[3H]Arachidonate and 56 93  3 4 1146 
[3H]Arachidonate and 53 91 4  5  1062 
[3H]Eicosapentaenoate 66 90 5  5 575 
inhibitors 
palmitate 
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FIG. 1. Identification and quantitation  of  radiolabeled fatty 
acids  released by alkaline methanolysis from platelet  proteins 
labeled with [3H]arachidonate ( A )  or [3H]eicosapentaenoate 
( B ) .  Using reverse-phase HPLC, elution positions of arachidonate 
(AA), methyl arachidonate ( M A A ) ,  and methyl 22:4 (M22:4) as well 
as those of eicosapentaenoate (EPA) ,  methyl eicosapentaenoate 
(MEPA),  and methyl 22:6 (M22:6) were determined by monitoring 
absorbance at 205 nm. Both elution profiles represent the mean 
values of duplicate experiments with essentially identical results. 
in  the arachidonoylated lane which corresponds to  the highly 
intense [3H]palmitoylated band at  37 kDa is especially no- 
ticeable on the nonreduced gel. These polypeptides either 
cannot be arachidonoylated or  the  extent of their arachidon- 
oylation is too low to appear  on the fluorogram. It was also 
found that [3H]eicosapentaenoate labeled the same set of 
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FIG. 2. 'H-Arachidonoylated  and  'H-palmitoylated  proteins 
in platelets. Washed platelets were labeled with [3H]fatty acid. 
Platelet  proteins were then precipitated, extracted, and dissolved in 
sample buffer. Reduced and nonreduced samples (40 pg protein/well) 
were analyzed by SDS-PAGE after which the radiolabeled proteins 
were detected by fluorography. SDS-PAGE of reduced samples was 
performed in duplicate on two parallel gels, and one of the fixed  gels 
was subjected to neutral hydroxylamine (+HA) treatment. Lanes C, 
Coomassie-stained gels of platelet proteins; lanes P, [3H]palmitate- 
labeled platelets; lams A ,  platelets incubated with [3H]arachidonate; 
lanes AI ,  [3H]arachidonate-labeled platelets incubated with baicalein 
and indomethacin to inhibit cyclooxygenase and lipoxygenase. Hori- 
zontal lines on the left side of first gel represent the migration distance 
of Mr marker proteins. Arrowheads on the P lane identify bands 
which can be detected only on the fluorogram of 3H-palmitoylated 
proteins. 
proteins as [3H]arachidonate (Fig. 3). As expected from the 
results of neutral hydroxylamine treatment of radiolabeled 
proteins in solution, hydroxylamine treatment of the gels 
completely eliminated the radiolabeled bands from the fluo- 
rogram of 3H-palmitoylated proteins (hydroxylamine-treated 
gel, lane P ) ,  while some of the arachidonoylated proteins, 
among them a 66-kDa polypeptide, retained its radiolabel 
(hydroxylamine-treated gel, lane A ) .  No change in the fluo- 
rographic pattern of arachidonoylated proteins could be de- 
tected when platelet cyclooxygenase and lipoxygenase were 
both  inhibited (lanes AI uersus  lanes A ) ,  although the lanes 
representing samples with  inhibitors were somewhat less in- 
tense  than those  without  inhibitors. 
DISCUSSION 
The primary purpose of this study was to determine if two 
polyunsaturated fatty acids which can be converted to biolog- 
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FIG. 3. Fluorograms of platelet proteins labeled with ['HI 
arachidonate and ['H]eicosapentaenoate. Reduced and unre- 
duced protein samples (50 pg protein/well) of platelets labeled with 
[3H]arachidonate (A) and [3H]eicosapentaenoate ( E )  were analyzed 
by SDS-PAGE and fluorography. 
ically active metabolites, arachidonate and eicosapentaenoate, 
could  be utilized for posttranslational  fatty acid acylation of 
proteins. To perform this study using nucleated cells with 
active protein synthesis would  impose a number of difficulties 
regarding interpretation of data on the posttranslational  in- 
corporation of radiolabeled fatty acids into the cells. In  nu- 
cleated cells with active protein synthesis, fatty acids can be 
@-oxidized, and the radiolabel may appear in amino acids 
utilized for protein synthesis, or in  fatty acids used for co- 
translational acylation of proteins. Therefore, platelets, which 
are highly important in hemostasis, provide an excellent tool 
for  specifically studying posttranslational  fatty acid acylation 
of proteins. 
The covalent binding of [3H]arachidonate or [3H]eicosapen- 
taenoate to platelet proteins was proven by several lines of 
evidence in  this study. First, in platelets radiolabeled with 
these fatty acids, the radiolabel was  recovered with protein 
after exhaustive lipid extraction to remove noncovalently 
associated lipids.  Second, the radiolabeled fatty acid  could not 
be separated from the proteins by SDS-PAGE. Third, the 
platelet-bound radioactivity was cleaved from the protein 
using techniques which selectively disrupt certain types of 
covalent bonds, and the released radioactivity was identified 
as the respective fatty acids by HPLC. It remains to be 
determined if the binding of [3H]arachidonate and [3H]eico- 
sapentaenoic to proteins is a platelet-specific process or, more 
likely, a generalized phenomenon. 
Lecomte et al. (22) have also studied protein labeling in 
platelets incubated with [3H]arachidonate. However, they 
found only minimal labeling of proteins  in resting platelets 
which  was significantly increased during activation by throm- 
bin. Based on experiments with cyclooxygenase,  lipoxygenase, 
and thromboxane synthetase inhibitors, they concluded that 
cyclooxygenase and lipoxygenase products, and not arachi- 
donate, were the moieties covalently bound to proteins, al- 
though the protein-linked moieties presumed to be eicosa- 
noids were not isolated and identified. The differences be- 
tween their findings and ours may be partly explained by 
different experimental conditions for fatty acid labeling of the 
proteins. In their experiments, the radioactivity used for 
labeling was significantly less; the labeling period was  much 
shorter,  and  the platelet count was  higher. As a result, the 
process of arachidonoylation in resting platelets could  have 
been below the limit of detection. It is  to be noted that under 
the conditions used in their experiments, palmitoylation of 
platelet proteins also could not be detected. It has been  shown, 
however, in our previous studies (16, 17) and in the work of 
others (30,31) that posttranslational modification of platelet 
proteins with palmitate is an active process. In the present 
study, the combined inhibition of lipoxygenase and cycloox- 
ygenase did not prevent radiolabeling of proteins by [3H] 
arachidonate, and  the radioactivity liberated from proteins by 
alkaline methanolysis was quantitatively recovered as arach- 
idonate. These findings indicate that  the fatty acid and not 
its eicosanoid metabolites was  bound to platelet proteins. 
The majority of protein-linked arachidonate and eicosapen- 
taenoate, and nearly all protein-bound palmitate in our ex- 
periments, was bound through thioester linkages.  Most of the 
palmitoylated proteins were also arachidonoylated, but sev- 
eral were only palmitoylated. This might indicate that there 
are two protein-S-fatty acyltransferases, only one of which 
utilizes polyunsaturated fatty acids. Alternatively, there could 
be substrate proteins to which polyunsaturated fatty acids 
cannot bind because unlike saturated  fatty acids, they are not 
straight chain molecules.  If the protein-linked [3H]fatty acid 
binding in our study is expressed as dpm/pg protein, the 
binding of [3H]palmitate to proteins was only 11% higher 
than  that of [3H]arachidonate, but when  expressed as percent 
of total incorporated [3H]fatty acid, the amount of protein- 
linked palmitate was three times greater than  the amount of 
protein-linked arachidonate. Although arachidonate is incor- 
porated into platelets much more rapidly and to a greater 
extent than palmitate, a much higher percentage of arachi- 
donate becomes esterified in phospholipids (26). This may 
indicate that relatively more  palmitoyl-CoA than arachidon- 
oyl-CoA is available for protein acylation and explain our 
observed results. Unlabeled palmitate in relatively high  con- 
centration competed with radiolabeled arachidonate for pro- 
tein binding to  a lesser extent  than expected on the basis of 
the above finding, and on the basis of its competition with 
the straight chain radiolabeled fatty acids [3H]palmitate and 
[3H]myristate. One  possible explanation for this observation 
is, as mentioned previously, that there may  be  two protein-S- 
fatty acyltransferases, only  one of which  utilizes polyunsatu- 
rated fatty acids. It may also be that in the concentration 
ranges used in our studies, the two fatty acids  do not compete 
effectively  for binding to proteins. 
The ester-bound arachidonate and eicosapentaenoate 
which are not thioester-linked probably represent fatty acids 
esterified to proteins through O-ester linkages. This may in- 
volve hydroxyl  groups of serine or threonine residues. Alter- 
natively, [3H]fatty acid  may  be incorporated into  the phos- 
phatidylinositol moiety of a protein-linked glycophosphati- 
dylinositol anchor. 
Protein-linked arachidonate represents a hitherto unrec- 
ognized cellular arachidonate pool, the compartmentalization 
of which depends on the compartmentalization of the proteins 
to which it is linked. The release of arachidonate from proteins 
by a putative protein-S-fatty acylesterase, if the conditions 
were suitable, may  even result in eicosanoid  production. It is 
to be emphasized that  the mass concentration of fatty acids 
used in these experiments resembles their physiological con- 
centrations  in  the plasma as nonesterified fatty acids  bound 
to albumin. This suggests that binding of these fatty acids to 
platelet proteins is a continuous process under normal con- 
18248 Fatty  Acid  Acylation of Proteins 
ditions. This also raises the possibility that  the composition 
of the  fatty acid pool linked to platelet  proteins depends on 
the composition of one or more pools of fatty acids in the 
plasma, such as the albumin-bound pool of nonesterified fatty 
acids. If this  is  true, changes in the concentration of certain 
plasma fatty acids may alter  the composition of fatty acids 
bound to proteins, which then could have structural and 
functional implications. The replacement of a protein-linked 
palmitate, for instance, with arachidonate, a fatty acid of 
different hydrophobicity and conformation, may significantly 
influence its relationship with membrane lipids or hydropho- 
bic domains of other  proteins. 
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